Charles River Laboratories International, Inc. (CRL) Stock Rating Reaffirmed by Citigroup Inc.

Citigroup Inc. reiterated their neutral rating on shares of Charles River Laboratories International, Inc. (NYSE:CRL) in a report published on Thursday, May 11th. The brokerage currently has a $104.00 target price on the medical research company’s stock, up from their prior target price of $90.00.

Separately, Jefferies Group LLC reaffirmed a buy rating and issued a $106.00 price target on shares of Charles River Laboratories International in a report on Friday, April 21st. Five research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus price target of $90.81.

Shares of Charles River Laboratories International (CRL) opened at 95.76 on Thursday. Charles River Laboratories International has a 12-month low of $67.20 and a 12-month high of $95.83. The company has a 50-day moving average of $91.73 and a 200 day moving average of $85.30. The firm has a market capitalization of $4.56 billion, a PE ratio of 28.02 and a beta of 1.00.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, May 10th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.14 by $0.15. The company had revenue of $445.80 million during the quarter, compared to analysts’ expectations of $437.04 million. Charles River Laboratories International had a return on equity of 27.46% and a net margin of 9.28%. The business’s revenue was up 25.6% on a year-over-year basis. During the same period last year, the business earned $0.98 earnings per share. On average, analysts predict that Charles River Laboratories International will post $5.10 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.com-unik.info/2017/06/17/charles-river-laboratories-intl-s-crl-neutral-rating-reiterated-at-citigroup-inc-updated-updated-updated.html.

In related news, insider David Ross Smith sold 945 shares of the business’s stock in a transaction that occurred on Thursday, June 8th. The stock was sold at an average price of $95.00, for a total value of $89,775.00. Following the completion of the transaction, the insider now directly owns 14,203 shares in the company, valued at approximately $1,349,285. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Davide Molho sold 10,976 shares of the business’s stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $92.84, for a total value of $1,019,011.84. Following the completion of the transaction, the insider now owns 27,525 shares of the company’s stock, valued at $2,555,421. The disclosure for this sale can be found here. Insiders have sold a total of 13,051 shares of company stock valued at $1,208,566 over the last 90 days. Corporate insiders own 2.20% of the company’s stock.

Several institutional investors have recently modified their holdings of CRL. Vanguard Group Inc. raised its position in shares of Charles River Laboratories International by 4.7% in the first quarter. Vanguard Group Inc. now owns 5,033,513 shares of the medical research company’s stock valued at $452,764,000 after buying an additional 225,563 shares in the last quarter. BlackRock Inc. boosted its stake in Charles River Laboratories International by 12,573.1% in the first quarter. BlackRock Inc. now owns 3,845,643 shares of the medical research company’s stock valued at $345,915,000 after buying an additional 3,815,298 shares during the last quarter. FMR LLC boosted its stake in Charles River Laboratories International by 39.7% in the first quarter. FMR LLC now owns 2,488,113 shares of the medical research company’s stock valued at $223,806,000 after buying an additional 707,612 shares during the last quarter. Ariel Investments LLC boosted its stake in Charles River Laboratories International by 30.7% in the first quarter. Ariel Investments LLC now owns 2,060,420 shares of the medical research company’s stock valued at $185,335,000 after buying an additional 483,564 shares during the last quarter. Finally, State Street Corp boosted its stake in Charles River Laboratories International by 1.1% in the first quarter. State Street Corp now owns 1,239,943 shares of the medical research company’s stock valued at $111,539,000 after buying an additional 13,759 shares during the last quarter. Institutional investors and hedge funds own 97.77% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

What are top analysts saying about Charles River Laboratories International Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Charles River Laboratories International Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit